Staphylococcus aureus (S. aureus) is considered by the World Health Organization as a high priority pathogen for which new therapies are needed. This is particularly important for biofilm implant-associated infections once the only available treatment option implies a surgical procedure combined with antibiotic therapy. Consequently, these infections represent an economic burden for Healthcare Systems. A new strategy has emerged to tackle this problem: for small bugs, small particles. Here, we describe how nanotechnology-based systems have been studied to treat S. aureus biofilms. Their features, drawbacks and potentialities to impact the treatment of these infections are highlighted. Furthermore, we also outline biofilm models and assays required for preclinical validation of those nanosystems to smooth the process of clinical translation.

中文翻译：

---

纳米系统对金黄色葡萄球菌生物膜治疗的影响。

金黄色葡萄球菌（金黄色葡萄球菌）被世界卫生组织视为需要新疗法的高度优先病原体。一旦唯一可用的治疗方案意味着将手术程序与抗生素治疗相结合，这对于与生物膜植入物相关的感染尤为重要。因此，这些感染代表了医疗保健系统的经济负担。已经出现了一种解决该问题的新策略：针对小缺陷，小颗粒。在这里，我们描述如何研究基于纳米技术的系统来治疗金黄色葡萄球菌生物膜。突出了它们的特征，缺点和影响这些感染治疗的潜力。此外，我们还概述了生物膜模型和那些纳米系统的临床前验证所需的生物测定，以简化临床翻译过程。